Legal Representation
Attorney
Beth M. Goldman
USPTO Deadlines
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 6, 2001 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Apr 2, 2001 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Feb 21, 2001 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Oct 18, 2000 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Aug 16, 2000 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Mar 1, 2000 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Mar 1, 2000 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Sep 7, 1999 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Sep 7, 1999 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Apr 1, 1999 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 4, 1999 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Sep 8, 1998 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 16, 1998 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 15, 1998 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Apr 8, 1998 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 13, 1998 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 15, 1997 | CNFR | O | FINAL REFUSAL MAILED | Loading... |
| Sep 9, 1997 | ZZZY | Z | PREVIOUS ACTION COUNT WITHDRAWN | Loading... |
| Nov 21, 1996 | CNRT | F | NON-FINAL ACTION MAILED | Loading... |
| Nov 7, 1996 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Detailed Classifications
Class 001
biochemicals, namely, monoclonal antibodies and fragments thereof for research and development, for general manufacturing and for use in the manufacture of pharmaceuticals; cell lines for research and development, for general manufacturing and for use in the manufacture of pharmaceuticals
First Use Anywhere:
0
First Use in Commerce:
0
Class 005
pharmaceuticals, namely, monoclonal antibodies and fragments thereof for clinical diagnostic and therapeutic use for the treatment of cancer, autoimmune diseases, infectious diseases, inflammatory diseases and genetic diseases; cell lines for clinical diagnostic and therapeutic use for the treatment of cancer, autoimmune diseases, infectious diseases, inflammatory diseases and genetic diseases
First Use Anywhere:
0
First Use in Commerce:
0
Class 031
animal embryos for laboratory use
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
pharmaceutical and biological product development consultation; and pharmaceutical and biological product development for others
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
001
005
031
042